[HTML][HTML] A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen… - Investigational New …, 2020 - Springer
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
[PDF][PDF] A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen, JCH Yang… - 2019 - d-nb.info
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colonystimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colonystimulating factor 1 receptor. This phase I …
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
JH Lee, TW Chen, CH Hsu, YH Yen… - Investigational new …, 2019 - europepmc.org
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
[HTML][HTML] A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen… - Investigational New …, 2020 - ncbi.nlm.nih.gov
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, CT Wei-Wu, CH Hsu, Y Yu-Hsin… - Investigational New …, 2020 - search.proquest.com
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
JH Lee, TWW Chen, CH Hsu, YH Yen… - Investigational …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Pexidartinib, a novel, orally administered small-molecule tyrosine kinase
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …
inhibitor, has strong selectivity against colony-stimulating factor 1 receptor. This phase I …